WO2018059576A1 - Sonde pour détection de mutation génétique de l'egfr humain, kit et procédé de détection associés - Google Patents

Sonde pour détection de mutation génétique de l'egfr humain, kit et procédé de détection associés Download PDF

Info

Publication number
WO2018059576A1
WO2018059576A1 PCT/CN2017/104777 CN2017104777W WO2018059576A1 WO 2018059576 A1 WO2018059576 A1 WO 2018059576A1 CN 2017104777 W CN2017104777 W CN 2017104777W WO 2018059576 A1 WO2018059576 A1 WO 2018059576A1
Authority
WO
WIPO (PCT)
Prior art keywords
detection
probe
solution
electric field
mutation
Prior art date
Application number
PCT/CN2017/104777
Other languages
English (en)
Chinese (zh)
Inventor
廖玮
莫亚勤
张晨光
Original Assignee
广州易活生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州易活生物科技有限公司 filed Critical 广州易活生物科技有限公司
Publication of WO2018059576A1 publication Critical patent/WO2018059576A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the invention is entitled "Probes, kits and detection methods for detecting human EGFR gene mutations” filed on September 30, 2016, the invention patent application with the application number 201610873223.8, and December 26, 2016 Submitted, the utility model name is "detection electrode structure and detection orifice plate", the priority of the Chinese utility model patent application with the application number 201620769829.2, the entire contents of the above two Chinese patent applications, hereby based on all purposes, by reference The manner of the invention is incorporated in the present invention.
  • the invention relates to the field of gene detection, in particular to a probe, a kit and a detection method thereof for detecting mutation of a human EGFR gene.
  • Non-small-cell Lung Cancer including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, has slower cell growth and division and relatively late diffusion and metastasis compared with small cell lung cancer. Lung cancer accounts for about 80-85% of the total number of lung cancers.
  • the Epidermal Growth Factor Receptor is a receptor for epidermal growth factor (EGF) cell proliferation and signaling.
  • EGFR belongs to the ErbB receptor family, which includes EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her3 (ErbB-3) and Her 4 (ErbB-4).
  • EGFR belongs to the tyrosine kinase type receptor. After EGFR binds to its ligand in the extracellular region, EGFR molecules form homodimers, and can also form heterodimers with other HER family molecules, followed by intracellular regions.
  • TK tyrosine kinase
  • PLC ⁇ , aCBL, GRB2, SHC, p85 The downstream coupled proteins (PLC ⁇ , aCBL, GRB2, SHC, p85) specifically bind to the phosphorylation site, transmitting signals downstream.
  • the RAS-MAPK pathway, PI3K-AKT pathway, STAT pathway, etc. activate proliferation, apoptosis escape, angiogenesis, metastasis and other biological behaviors closely related to tumor development.
  • overexpression of EGFR gene is frequently found, and it is also related to prognosis. Therefore, EGFR has attracted much attention as a molecular target.
  • EGFR mutant genes are associated with the use of tyrosine kinase inhibitors (TKI), including Iressa (Iressa) and Tarceva (Troquet), and EGFR gene mutations affect TKI.
  • TKI tyrosine kinase inhibitors
  • EGFR mutations mainly include four types: exon 19 deletion mutation, exon 2l point mutation, exon 18 point mutation and exon 20 insertion mutation. It has been found that more than 90% of the mutations in the EGFR gene are located in exons 19 and 21, and the most common EGFR mutations are the exon 19LREA deletion and the exon 21L858R mutation, both of which result in activation of the tyrosine kinase domain, and All of them are sensitive mutations in TKI.
  • the T790M mutation in exon 20 is associated with acquired resistance to EGFR-TKI, and the clinical significance of many types of mutations is still unclear.
  • the positive rate of EGFR gene-sensitive mutations in lung adenocarcinoma patients is about 10% in the Caucasian population, and about 50% in the Asian population and in China.
  • the detection of EGFR gene mutation is mainly divided into the detection of tumor tissue samples and the detection of circulating tumor DNA (ctDNA).
  • tumor tissue samples obtained by biopsy or surgery are mainly used to detect EGFR gene mutations, but invasive methods are required for obtaining tumor tissue specimens, which often increases patient suffering and creates additional surgical risks.
  • the tumor is heterogeneous.
  • For a cancer patient who has already metastasized only taking a certain part of the cancer tissue by puncture or surgery does not reflect the overall condition of the patient.
  • some patients' own conditions determine that they are not suitable for tissue biopsy, and some tumors have the risk of accelerating metastasis after being disturbed by puncture or surgery.
  • the organization of biopsy has many problems such as high cost and long waiting time, and its hysteresis is also unfavorable for the treatment of patients.
  • liquid biopsy the concept of "liquid biopsy” is emerging.
  • the basic idea is to use blood samples such as blood to replace tumor tissue samples for pathology and molecular biology, and to detect tumor circulation in body fluid samples (mainly blood).
  • DNA has become a trend to obtain information on tumor gene mutations.
  • revolutionary liquid biopsy has the following irreplaceable advantages: small trauma, reproducibility, homogenization heterogeneity, real-time judgment of efficacy, and dynamic adjustment of treatment decisions as the tumor progresses. Therefore, the 2015 MIT Technology Review released the annual breakthrough technology (Breakthrough Technologies 2015), ASCO annual progress (Clinical In the cancer advance 2015), liquid biopsy is on the list for the next decade.
  • ctDNA By detecting ctDNA to track specific gene changes in tumors throughout the course of the disease, it is of great value for tumor screening, diagnosis, efficacy monitoring and prognosis judgment. It can also explore the molecular mechanism of tumor metastasis, recurrence and drug resistance, and identify new targets. To the treatment site, etc., the detection of ctDNA has become one of the three hot trends in tumor liquid biopsy applications (note: the other two are CTC and exosomes).
  • the main methods for detecting gene mutations include direct sequencing (PCR-sanger sequencing), Amplification refractory mutation system (ARMS), and Denaturing high-performance liquid chromatograph (DHPLC). High resolution melting (HRM), allele-specific Taqman polymerase chain reaction (CAST-PCR), digital PCR (dPCR), High-throughput sequencing (HTS) and the like.
  • Direct sequencing method Direct sequencing method firstly designed PCR primers for the mutation site, and obtained the target gene fragment by PCR amplification. Then the sanger sequencing of the PCR product was carried out and the sequencing results were analyzed. After the preliminary analysis is completed, the PCR product of the sample which may carry the mutation information needs to be recovered by a method such as gelatinization, and the recovered PCR product is ligated to the cloning vector (generally a plasmid), and the positive clone is selected for sequencing to confirm the mutation.
  • the cloning vector generally a plasmid
  • the method utilizes the principle that the 3'-end base of the PCR primer must be complementary to the template DNA for efficient amplification, and the specific PCR amplification primer for the mutation site is designed. Under strict amplification conditions, only the primer 3' When the base is paired with the template, the PCR reaction can proceed normally, thereby detecting the mutation.
  • two upstream primers one of the 3' ends is complementary to the normal gene sequence, and the other 3' end is complementary to the mutated gene sequence.
  • Two upstream primers and a common downstream primer are added for detection, and two parallel PCR, based on the results of two PCR reactions, can distinguish whether there is a mutation and whether the mutation is homozygous or heterozygous.
  • the detection sensitivity of the ARMS method is about 1%.
  • the method has the advantages that both known and unknown mutations can be detected, but the target gene fragment needs to be obtained by PCR before the detection, and the reaction process needs to open the reaction tube, which is easy to cause pollution, the detection sensitivity is about 5%, and for the positive result. It is not possible to determine the specific type of mutation, and ultimately requires sequencing verification.
  • the method is based on the physical properties of the nucleic acid fragment, and the gene mutation is analyzed by monitoring the dissolution curve of the PCR product by binding the saturated dye to the PCR amplification product.
  • the detection sensitivity of this method is about 5%. For the positive result, the specific mutation type cannot be determined, and finally the sequencing verification is needed.
  • Allele-specific Taqman polymerase chain reaction uses an optimized Taqman probe to block the binding of PCR primers to wild-type DNA by a specific MGB probe, so that the mutant DNA can be preferentially amplified, and the sensitivity of the detection method is about 1%.
  • Digital PCR is a method of absolute quantification based on single-molecule PCR methods for counting nucleic acids.
  • the microfluidic or microtiter method is mainly used to disperse a large amount of the diluted nucleic acid solution into the microreactor or droplet of the chip, and the number of nucleic acid templates per reactor is less than or equal to one.
  • the reactor with one template of the nucleic acid molecule gives a fluorescent signal, and the reactor without the template has no fluorescent signal.
  • the nucleic acid concentration of the original solution can be derived.
  • the detection sensitivity of digital PCR is about 0.1%.
  • the biggest advantage of this technology is its high throughput, which can simultaneously sequence multiple samples in parallel.
  • unknown mutations can be found, and the detection sensitivity is about 1-5%.
  • the detection process of high-throughput sequencing generally includes DNA extraction and purification, construction of libraries, sequencing template preparation, sequencing, and biological information analysis.
  • the direct sequencing method has the advantage of being able to determine the range and type of mutation.
  • the sensitivity is not high, and only the gene mutation with the content greater than 20% can be detected, which is far from satisfactory.
  • Practical application Need especially for heterogeneous tumor somatic mutations, low sensitivity will result in a large number of missed tests.
  • the sequencing method has complicated detection operation and poor timeliness. The limitations of sequencing methods have been highlighted for the practical application of high timeliness and high sensitivity.
  • Amplification of the repressor mutation system requires real-time quantitative PCR detection technology, each pair of primers can only detect one mutation, and each mutation needs to establish a separate PCR reaction system, and it is cumbersome to detect multiple detection sites of multiple samples at the same time. Moreover, the method needs to extract purified DNA, and the requirement for the sample is large, and it is not suitable for detecting multiple gene mutation sites at the same time, and the PCR operation process is prone to aerosol pollution, which brings a risk of false positive.
  • the allele-specific Taqman polymerase chain reaction also has the same disadvantages.
  • Denaturing high performance liquid chromatography and high resolution dissolution curve method and for the positive results can not determine the specific mutation type, and finally need to be verified by sequencing.
  • the detection sensitivity of the two methods is about 5%, which cannot meet the needs of practical applications.
  • One aspect of the present invention is to provide a probe set for detecting a mutation in a human EGFR gene, which consists of a capture probe and a detection probe that specifically captures a mutation site of a human EGFR gene, and a detection probe The side sequence of the mutation site is detected to achieve the purpose of accurate detection.
  • the contribution of the second aspect of the present invention is to provide a detection plate, a kit and a detection method for detecting human EGFR gene mutation based on EFIRM technology, and the kit requires only a small amount of sample detection, and the detection process utilizes an electric field to accelerate the reaction rate and shorten the reaction. Time, the entire inspection process can be completed in half an hour, greatly reducing the time required for testing, and high detection sensitivity and accuracy.
  • the invention provides a probe for detecting a mutation of a human EGFR gene, the probe comprising any one or more of a pair of 1-35 probes, each of which comprises a capture probe and a detection probe;
  • nucleotide sequence of the 1-35 probe pair is as shown in SEQ ID NO: 1-70 of the Sequence Listing;
  • the probe provided by the present invention is designed in sequence according to the wild type sequence shown in SEQ ID NO: 71-91, 127-129 and the mutant sequence shown in SEQ ID NO: 92-126, wherein 1-35 probe Targeting to the mutant sequence shown in SEQ ID NOs: 92-126;
  • mutant sequence set forth in SEQ ID NO: 96, 97, 99, 100, 101, 103, 111, 112, 113, 115 corresponds to the wild type sequence set forth in SEQ ID NO:73.
  • the correspondence between all the mutant sequence numbers and the wild type sequences is shown in the table.
  • the 1-35 probe pair corresponds in turn to the above-described mutant sequence and wild type sequence.
  • the 1-3 probe pair in the probe for detecting human EGFR gene mutation provided by the present invention is designed for the exon 18 point mutation of EGFR, and the 4-28 probe pair is the exon 19 deletion mutation for EGFR.
  • the 29-33 probe pair is designed for exon 20 mutations of EGFR, and the 34-35 probe pair is designed for exon 21 point mutations of EGFR.
  • the nucleotide sequence of the 1-3 probe pair is as shown in SEQ ID NO: 1-6; the nucleotide sequence of the capture probe in the probe pair is as shown in SEQ ID NO: 1, detecting The needle is shown in SEQ ID NO: 2; the nucleotide sequence of the capture probe in the 2 probe pair is shown in SEQ ID NO: 3, and the detection probe is shown in SEQ ID NO: 4. Accordingly, the remaining pairs of probes are analogous.
  • the capture probe obtained by the multiple screening of the invention cooperates with the detection probe, has high sensitivity and strong specificity, and can detect various samples containing the target sequence, and the result is accurate and reliable.
  • the present invention uses the change of the electrical signal to realize the detection of the EGFR gene mutation site.
  • the detection probe is provided with a label, and the label is preferably digoxin, biotin, isothiocyanate. Any of the acid fluorescein labels.
  • the detection probe binds to the subsequently added enzyme with the corresponding label to provide a basis for detecting changes in the electrical signal.
  • the invention is based on the above probe set disclosed by the invention, and provides a detection plate for detecting mutation of human EGFR gene based on EFIRM technology, wherein the bottom of the reaction hole is provided with an electrode for connecting the EFIRM detector.
  • An electric field is applied to the solution in the reaction well, and the reaction wells are dispensed and fixed with capture probes in the probe combination, and each of the reaction wells is fixed with one of the capture probes.
  • the capture probe is mixed with the immobilizer, and is attached to the reaction well of the detection orifice by an electric field;
  • the fixture comprises a conductive polymer material and a salt ion compound
  • the conductive polymer material is selected from at least one of aniline, thiophene and pyrrole conductive molecular monomers;
  • the salt ionic compound is at least one selected from the group consisting of a chloride salt, a nitrate salt, and a sulfate salt.
  • the present invention also provides a method for preparing the above detection orifice plate, wherein the capture probe is mixed with the immobilization material as a capture solution,
  • Adding the capture solution to the reaction well of the blank detection well plate, and the bottom of the reaction well is provided with an electrode for turning on the EFIRM detector to apply an electric field to the solution in the reaction well for polymerization;
  • the composition of the capture solution is as follows: the volume percentage of the conductive polymer material is 0.1% to 5%, the concentration of the salt ion compound is 0.01 mol/L to 2 mol/L, and the concentration of the capture probe is 0.5-1.5 ⁇ mol/ L.
  • the conductive polymer material is selected from at least one of aniline, thiophene and pyrrole conductive molecular monomers;
  • the salt ionic compound is selected from at least one of a chloride salt, a nitrate salt, and a sulfate salt;
  • the parameters of the electric field are as follows: voltage A: 350 mV, 1 s; voltage B: 950 mV, 1 s; 5 cycles are performed.
  • the present invention also provides a human EGFR gene mutation detection kit, comprising at least one of the above probes, an enzyme, and a substrate corresponding to the enzyme;
  • the enzyme is labeled with a substance that binds to a label provided on the detection probe.
  • the enzyme-labeled substance is correspondingly a digoxin antibody or a fluorescein isothiocyanate antibody;
  • the enzyme-labeled substance is avidin.
  • the detection probe and the enzyme can be bound by means of FITC and anti-FITC antibody or digoxin and digoxin antibody or avidin such as streptavidin and biotin.
  • the enzyme is a horseradish peroxidase polymer (abbreviated Poly-HRP) or an alkaline phosphatase;
  • Poly-HRP horseradish peroxidase polymer
  • alkaline phosphatase alkaline phosphatase
  • the substrate is a mixture of TMB and H 2 O 2 , O-phenylenediamine (OPD), ABTS [2, 2'-azino-di- Any of (3-ethylbenziazobine sulfonate-6)], 3-(4-hydroxy);
  • the product after oxidation of OPD is dark orange or brown, and the product of ABTS reaction is blue-green.
  • the substrate is a composition of p-nitropheny-phosphate disodium salt (pNPP), BCIP and NBT, disodium 4-nitrobenzene phosphate, naphthol Any of AS-BI phosphate, naphthol-AS-MX-phosphate.
  • pNPP p-nitropheny-phosphate disodium salt
  • BCIP p-nitropheny-phosphate disodium salt
  • NBT disodium 4-nitrobenzene phosphate
  • naphthol Any of AS-BI phosphate, naphthol-AS-MX-phosphate.
  • pNPP produces a yellow water-soluble reaction product under the action of alkaline phosphatase
  • BCIP and NBT are one of the best chromogenic substrate combinations of alkaline phosphatase, the product is dark blue; disodium 4-nitrophenyl phosphate
  • the product is yellow soluble; naphthol AS-BI phosphate, the product is red insoluble; naphthol-AS-MX-phosphate, the product is red insoluble.
  • the EGFR gene mutation detection kit provided by the invention provides convenient detection of EGFR gene mutation.
  • the kit further includes a fixture for immobilizing the capture probe, a hybridization buffer, a blocking protein, a PBS, a washing solution, and a detection well plate.
  • the specific structure of the detection orifice is shown in the name of the detection electrode and the detection orifice in the detection orifice as disclosed in the application No. 201620769829.2.
  • the blocking protein is any one of casein, fetal bovine serum, and calf serum.
  • kits provided by the present invention may be present alone or in the form of a mixed solution.
  • the fixture comprises a conductive polymer material and a salt ion compound
  • the conductive polymer material is any one of aniline, thiophene and pyrrole conductive molecular monomers
  • the salt ionic compound is any one of a chloride salt, a nitrate salt, and a sulfate salt.
  • the salt may be sodium, potassium, magnesium, ammonium or the like; for example, the chloride salt may be sodium chloride, potassium chloride, magnesium chloride, ammonium chloride, etc.
  • the nitrate may be sodium nitrate, potassium nitrate or nitric acid.
  • the sulfate may be sodium sulfate, potassium sulfate, magnesium sulfate, ammonium sulfate or the like.
  • the first step is to fix the capture probe on the detection well plate by polymerization under electric field conditions, which provides a basis for subsequent detection.
  • the capture probe and the immobilizer are present in the form of a capture solution containing the following components: a volume percentage of the conductive polymer material of 0.1% to 5%, salt
  • concentration of the ionic compound is from 0.01 mol/L to 2 mol/L
  • concentration of the capture probe is from 0.5 to 1.5 ⁇ mol/L.
  • the capture solution can be directly added to the reaction well of the detection well plate.
  • the volume of each reaction well is about 300 ⁇ l, and 20-80 ⁇ l of the capture solution is added. All right.
  • the capture probe and the fixture are attached to the detection orifice plate;
  • the capture solution is prepared by adding the capture solution to the reaction well of the detection well plate, and then washing it after the electric field treatment.
  • the procedure is: cleaning procedure from the bottom: aspirating while injecting liquid; cleaning procedure from top to bottom: first injecting liquid, then aspirating; repeating the above steps.
  • a mixture of the sample to be tested and the hybrid buffer is added, wherein the hybrid buffer is treated in a water bath at 85-95 ° C for 5-15 min, then left to cool to room temperature, and mixed with the sample to be tested at a volume ratio of 1:1.5-2.5. Then, 20-80 ⁇ l was added to the reaction well of the detection well plate, subjected to electric field treatment, and then washed by the same washing step as above.
  • the hybridization buffer of the present invention provides a good environment for hybridization of the probe, and any hybridization buffer that achieves this function is within the scope of the present invention.
  • the hybridization buffer as used may be any one of the following;
  • Hybridization buffer 1 containing Ficoll 400 1g / L, PVP360 1g / L, BSA 1g / L, NaH 2 PO 4 80mM, Na 2 HPO 4 420mM, EDTA 2.5mM, SDS 6g / L, NaCl 43.8g / L, dihydrate Sodium citrate 36.9 g/L, pH 7-8; the buffer was heated to 65 °C prior to use.
  • Hybrid buffer 2 in this solution, the volume percentage of 20 ⁇ SSC is 10%, the volume percentage of 100 ⁇ Denhardt is 5%, the mass concentration of Denatured salmon DNA is 0.1 mg/ml, and the volume percentage of formamide is 40%;
  • Hybrid buffer 3 50% formamide, 2 x SSC, 10% dextran sulfate (pH 7);
  • Hybrid buffer 4 1.5 M NaCl, 40 mM sodium phosphate buffer pH 7.2, 10 mM EDTA pH 8, 10 x Denhardt's solution, 0.2% SDS;
  • Hybrid buffer 5 20-100 nM Tris-HCl, 20-200 nM MgCl 2 , 0.01%-5% dextran sulfate;
  • Hybrid buffer 6 5 ⁇ SSC, 1% blocking protein, 0.1% N-lauroyl sarcosine, 0.02% SDS;
  • Hybrid buffer 7 0.5 M sodium dihydrogen phosphate, pH 7.5; 10 mM EDTA, 7% SDS.
  • the percentages in the above hybrid buffer refer to the mass percentage, and the content of each component is also the final concentration of each component in the whole solution.
  • the detection probe is present in the form of a detection solution
  • the detection solution is PBS as a solvent, wherein the weight percentage of the blocking protein is 0.1% to 5%, and the concentration of the detection probe is 0.5 to 1.5 ⁇ mol/L.
  • the role of blocking proteins such as casein in the detection solution is to block non-specific sites in the assay to increase the sensitivity and accuracy of the assay.
  • the enzyme is in the form of an enzyme solution
  • the enzyme solution is PBS as a solvent, wherein the weight percentage of the blocking protein is 0.1% to 5%, and the volume percentage of the enzyme is 0.05% to 0.2%.
  • the enzyme solution also contains a blocking protein.
  • the enzyme solution is added in an amount of 20-80 ⁇ l, incubated at room temperature for 20-40 min, and the well plate is washed for cleaning, and the washing procedure is repeated one more time than the above washing procedure.
  • the cleaning solution comprises a 0.1 ⁇ SSC-2 ⁇ SSC mixture containing a mass concentration of 0.04% to 0.06% SDS and a PBS solution containing a volume percentage of 0.05% to 0.15% Tween20.
  • PBST (0.1% Tween 20) 1 L: 949 ml of double distilled water was added to 50 ml of 20 ⁇ PBS, mixed, and 1 ml of Tween 20 was added and mixed.
  • the steps before adding the enzyme liquid are all washed with a 0.1 ⁇ SSC-2 ⁇ SSC mixture having a mass concentration of 0.04%-0.06% SDS, and washed with PBST after adding the enzyme.
  • the above-mentioned mixed liquid of the present invention is the concentration of the working liquid.
  • the mother liquid may be first prepared in accordance with the concentration of the above working liquid, and may be appropriately diluted at the time of use. Therefore, a corresponding concentration of the mother liquor is also within the scope of the present invention.
  • 20 ⁇ PBS 1L formula is: potassium dihydrogen phosphate: 5.4g, disodium hydrogen phosphate: 28.4g, sodium chloride: 160g, potassium chloride 4g, Add about 800 mL of deionized water to dissolve thoroughly, then add concentrated hydrochloric acid to adjust the pH to 7.4, and finally make up to 1 L.
  • PBS is 1 ⁇ PBS, and 20 ⁇ PBS can be diluted 20 times.
  • the cleaning solution is also generally configured with a high concentration of SSC and SDS, and then the corresponding dilution can be performed.
  • the human EGFR gene mutation detection kit provided by the invention has the advantages of being precise, reliable, fast, convenient and economical, and is advantageous for repeated sampling and detection, and has wide application range, and the sampling is harmless to the human body.
  • the ideal liquid biopsy product is provided by the invention.
  • the invention also provides a method for detecting a mutation in a human EGFR gene, comprising the steps of:
  • the capture probe comprising the probe set according to claim 1 or 2 is added to a blank detection well plate, and the bottom of the reaction well is provided with an electrode for applying the solution in the reaction well after the EFIRM detector is turned on.
  • the electric field is subjected to a polymerization reaction; after the EFIRM detector is turned on, a first electric field is applied to the solution in the reaction well to carry out a polymerization reaction; after the electric field treatment is completed, the detection orifice plate is cleaned;
  • the parameters of the first electric field processing are: voltage 200-500 mV, 1-5 s; voltage 800-1500 mV, 1-5 s; 3-10 cycles;
  • the detection solution contains the detection probe in the probe set according to claim 1 or 2, and the concentration is 0.5-1.5 ⁇ mol/L;
  • the sample to be tested is a body fluid
  • the body fluid includes plasma, saliva, and pleural effusion.
  • the enzyme solution is PBS as a solvent, wherein the weight percentage of the blocking protein is 0.1% to 5%, and the volume percentage of the enzyme is 0.05% to 0.2%.
  • the cleaning solution comprises a 0.1-2 x SSC mixture containing a mass concentration of 0.04% to 0.06% SDS and a PBS solution containing a volume percentage of 0.05% to 0.15% Tween20.
  • the detection solution is PBS as a solvent, wherein the weight percentage of the blocking protein is 0.1% to 5%, and the concentration of the detection probe is 0.5-1.5 ⁇ mol/L.
  • the invention provides a method for detecting a mutation of a human EGFR gene, a capture solution is added to a detection well plate, a polymerization reaction occurs under the action of an electric field, and a capture probe is immobilized on the bottom of the plate; then a detection sample is added, and a capture probe captures a target gene mutation sample; The detection solution is added, and the biotin-labeled detection probe detects the sequence flanking the mutation site; the enzyme solution is added, the enzyme recognizes and binds to the biotin of the detection probe through the labeled avidin; and the substrate of the enzyme is added to generate oxidation.
  • the reduction reaction generates a current, and the detection of the current signal completes the entire detection process.
  • the prior art is based on PCR technology.
  • DNA needs to be extracted and purified from the specimen, and then DNA amplification is required for PCR amplification.
  • NGS is subjected to DNA extraction and purification, construction of a library, sequencing template preparation, and sequencing.
  • the operation steps are complicated and the operation requirements are extremely high. Therefore, if ARMS-PCR and digital PCR technology are used in clinical practice, it takes 1-3 days to report. It takes 1-2 weeks for NGS technology to report. For tumor diseases that need to take appropriate treatment measures against time, this is the case. The reporting cycle severely limits its clinical application.
  • the kit provided by the invention detects exo-biomarkers by electric field induced release and measurement (EFIRM).
  • EFIRM electric field induced release and measurement
  • amplification only about 50 ⁇ l of the plasma or saliva sample to be tested and the detection reagent are added to the corresponding reaction wells of the detection well plate, and then the detection well plate is placed in the retention structure disclosed in application number 201610658321.X and includes
  • the structure detector ie EFIRM instrument
  • the detection process utilizes the action of the electric field to speed up the reaction rate and shorten the reaction time. The entire detection process can be completed in half an hour, which greatly shortens the detection time.
  • the sensitivity of ARMS is about 1%, and the sensitivity of NGS using PCR amplicon sequencing or capture sequencing is about 1-5% left. Right, the highest sensitivity is digital PCR, which is about 0.1%.
  • the sensitivity of the invention for detecting ctDNA by using EFIRM technology can reach 0.1%, which is equivalent to digital PCR, and reaches the advanced level of current ctDNA detection technology.
  • ctDNA has severe fragmentation (average length of only 166 bp), low content (less than 1% of peripheral blood free DNA), and short half-life (about 2 hours). The requirements are extremely high.
  • the accuracy of products based on ARMS-PCR technology is generally about 60-70%, which is far from the clinical demand, thus seriously restricting its clinical application.
  • the human EGFR gene mutation detection kit provided by the invention has a precision of more than 95% in comparison with the biopsy results in the clinical pre-test, and the accuracy of the digital PCR technique is only about 70% in the same period. Therefore, the accuracy is obviously superior to the existing one. Products on the market. (3) low cost
  • fluorescence signal detection is currently used in both ARMS-PCR and digital PCR.
  • the detection equipment needs to be equipped with an expensive fluorescence detection system. Therefore, the market price of the fluorescent quantitative PCR instrument used in ARMS-PCR technology is in the dozens. About 10,000 yuan, and the digital PCR instrument is more than 1 million yuan.
  • the high-throughput sequencer used in NGS technology whether it is optical sequencing represented by illumina or semiconductor sequencing system represented by ion proton, the market price is as high as several million yuan, and the high price severely restricts its Clinical promotion and application.
  • the present invention uses an electric field-guided release and measurement technique, the detection process utilizes an electric field, the reaction is fast, and the final result is detected in the form of an electrical signal, so the detection device is not equipped with expensive fluorescence like ARMS-PCR and digital PCR.
  • the detection system so the cost of the equipment is greatly reduced, only about half of the fluorescence quantitative PCR instrument, less than one tenth of the high-throughput sequencer.
  • EFIRM technology is based on the principle of nucleic acid hybridization, using a uniquely designed electrochemical technique, the detection probe does not need to be fluorescently labeled like ARMS-PCR, and because of the steps of DNA extraction and purification, The cost of the test reagent is greatly reduced compared to this. Compared with NGS, DNA extraction and purification, library construction, sequencing template preparation, and sequencing are used. Compared with multiple kits, EFIRM's reagent cost is more than 90%, and the competitive advantage is obvious.
  • EFIRM Since the use of EFIRM does not require DNA extraction and PCR amplification, there is no problem of easy contamination of PCR. In clinical use, it is not necessary to establish a clinical gene amplification laboratory, and the operator does not need to obtain a clinical gene amplification approval permit. The operation of general technicians makes the threshold of clinical application of liquid biopsy technology greatly reduced, which is conducive to the wide-scale promotion of liquid biopsy technology.
  • the existing ARMS-PCR, digital PCR and NGS technologies can only be carried out in a few large-scale top three hospitals with conditions. The status quo.
  • FIG. 1 is a schematic plan view showing a structure of a detecting electrode used in the method of the present invention
  • FIG. 2 is a schematic plan view showing another structure of a detecting electrode used in the method of the present invention.
  • FIG. 3 is a schematic plan view showing another structure of a detecting electrode used in the method of the present invention.
  • FIG. 4 is a schematic plan view showing another structure of a detecting electrode used in the method of the present invention.
  • Figure 5a is a schematic perspective view of a detection orifice plate used in the method of the present invention.
  • Figure 5b is a schematic plan view of a detecting orifice plate used in the method of the present invention.
  • Figure 6 is a partial perspective view of a detecting orifice plate used in the method of the present invention.
  • Figure 7 is a partial perspective view showing another detecting orifice plate used in the method of the present invention.
  • Figure 8 is a partial perspective view showing another detecting orifice plate used in the method of the present invention.
  • Figure 9 is a partial side elevational view of a detection orifice plate employed in the method of the present invention.
  • the EFIRM detector used in the present invention is produced by Guangzhou Yihuo Biotech Co., Ltd., and is described in "Felvi Chemical Sensor for Multiplex Biomarkers Detection, Clin Cancer Res. 2009 Jul 1; 15 (13) published by Fang Wei et al. In 4446–4452, the electrochemical detector used therein.
  • a general instrument pair capable of generating a square wave can be employed by those skilled in the art.
  • the square wave (csw E-field) applied to the reaction well can also be realized by using the EFIRMY instrument and related software developed by Yihuo Biotechnology Co., Ltd.
  • the capture probe is fixed at the bottom of the detection orifice plate.
  • the electric field parameters are set to: voltage A: 350 mV, 1 s; voltage B: 950 mV, 1 s; 5 cycles. After the electric field is processed, remove it immediately and clean the detection orifice.
  • the hybrid buffer (using the hybrid buffer 1 in the Summary of the Invention) was treated in a water bath at 90 ° C for 10 min in a water bath and then allowed to cool at room temperature for 20 min.
  • the samples were taken out from the -20 ° C refrigerator and thawed in a 4 ° C refrigerator. After complete dissolution, the sample and the hybrid buffer are mixed at a volume ratio of 1:2, vortexed and centrifuged, and the sample can be tested.
  • a blank control buffer, a corresponding concentration of the negative control (WT) and a positive control (MT) were added to the corresponding wells, and the amount of the sample was 30 ⁇ l.
  • WT negative control
  • MT positive control
  • the electric field parameters are set to: voltage A: 300 mV, 1 s; voltage B: 500 mV, 1 s; 5 cycles. After the electric field is processed, remove it immediately and clean the detection orifice.
  • casein/PBS solution containing 2% by weight of casein was taken from a refrigerator at 4 ° C. Take a 1.5 mL centrifuge tube, add 990 ⁇ l of casein/PBS, add 10 ⁇ l of 100 ⁇ M DP, vortex and mix, centrifuge, and set aside.
  • the electric field parameters are set to: voltage A: 300 mV, 1 s; voltage B: 500 mV, 1 s; 5 cycles. After the electric field is processed, remove it immediately and clean the detection orifice.
  • TMB/H2O2 solution (purchased from thermo fisher, product no. 34022, named as
  • the electric field parameter is set to: voltage A: -200mV, 60s, and the current reading is obtained.
  • different detection samples include a negative group and a positive group, and the genes determined by the negative group are corresponding wild type sequences, and the genes determined by the positive group are corresponding mutant sequences, and 20 parallel holes are set for each sample for detection.
  • cv coefficient of variation
  • rsd coefficient of dispersion or relative deviation
  • the human EGFR gene mutation detecting kit provided by the present invention and the sample for detecting the human EGFR gene mutation using the kit can detect a sequence content as low as 1 pM, and the detection sensitivity is high;
  • the range of values detected is less than 15%, and some even as low as 3%, and the detection stability is good. In addition, the detection of different concentrations of negative and positive samples, the measured values have a very good linear relationship.
  • test data for different samples is shown in Table 5-7.
  • Negative coincidence rate b / (b + d) ⁇ 100%.
  • both the plasma sample and the saliva sample or the pleural effusion sample have a good clinical test coincidence rate, and the accuracy rate is high, exceeding 95%, meeting the needs of clinical testing applications.
  • the above method detects the negative sample and the positive sample, the difference in the detected current values is large, and the different samples can be well distinguished.
  • a negative sample of saliva is detected using a 34 probe pair, and the current value is 41.6 to 65.6 (-nA), while the current value of the positive sample is 88.4 to 141.4 (-nA); correspondingly, the same plasma sample is used.
  • the negative sample obtained current value was 40.1 ⁇ 63.7 (-nA), while the positive sample current value was 83.6 ⁇ 139.2.
  • the human EGFR gene mutation detection kit provided by the invention and the detection of the human EGFR gene mutation using the kit are simple and convenient, the sample is non-invasive, and the required sample is small, and the whole detection process can be completed in half an hour; Good performance, can reach 0.1%, high accuracy, more than 95%; low cost, compared with NGS, cost savings of more than 90%; easy to operate, low requirements for operators.
  • test sample the specific steps are as follows:
  • the capture probe is fixed at the bottom of the detection orifice plate.
  • the capture solution contained the following components: 5% by weight of thiophene, 2 mol/L of NaCl, and 1.5 ⁇ mol/L of capture probe.
  • the corresponding column for the experiment was selected on the EFIRM software.
  • the electric field parameters were set to: voltage A: 500 mV, 1 s; voltage B: 1500 mV, 1 s; 10 cycles were performed. After the electric field is processed, remove it immediately and clean the detection orifice.
  • the hybrid buffer (using the hybrid buffer 3 in the Summary of the Invention) was treated in a water bath at 95 ° C for 5 min in a water bath and then allowed to cool at room temperature.
  • the samples were taken out from the -20 ° C refrigerator and thawed in a 4 ° C refrigerator. After complete dissolution, the sample is mixed with the hybrid buffer by a volume ratio of 1:2.5, vortex After centrifugation and centrifugation, the sample can be tested.
  • a blank control buffer, a corresponding concentration of the negative control (WT) and a positive control (MT) were added to the corresponding wells, and the sample volume was 80 ⁇ l.
  • WT negative control
  • MT positive control
  • the tip of the gun is attached to the bottom of the hole, but the bottom electrode is not touched.
  • the tilting or tapping of the detecting plate allows the liquid to uniformly cover the surface of the electrode in the hole, and then immediately goes to the EFIMR for electric field operation.
  • the corresponding column for the experiment was selected on the EFIRM software.
  • the electric field parameters were set to: voltage A: 500 mV, 1 s; voltage B: 800 mV, 1 s; 10 cycles were performed. After the electric field is processed, remove it immediately and clean the detection orifice.
  • the detection solution was PBS as a solvent, wherein the weight percentage of casein was 5%, the concentration of the detection probe was 1.5 ⁇ mol/L, vortexed and mixed, centrifuged, and set aside.
  • the corresponding column for the experiment was selected on the EFIRM software.
  • the electric field parameters were set to: voltage A: 500 mV, 1 s; voltage B: 800 mV, 1 s; 8 cycles were performed. After the electric field is processed, remove it immediately and clean the detection orifice.
  • TMB/H2O2 solution (purchased from thermo fisher, product no. 34022, named as
  • the electric field parameter is set to: voltage A: -300mV, 100s, and the current reading is obtained.
  • test sample the specific steps are as follows:
  • the capture probe is fixed at the bottom of the detection orifice plate.
  • the capture solution contained the following components: the weight percentage of aniline was 0.1%, the concentration of NaCl was 0.01 mol/L, and the concentration of the capture probe was 0.5 ⁇ mol/L.
  • the corresponding column for the experiment was selected on the EFIRM software.
  • the electric field parameters were set to: voltage A: 200 mV, 5 s; voltage B: 800 mV, 5 s; 3 cycles were performed. After the electric field is processed, remove it immediately and clean the detection orifice.
  • the hybrid buffer (using the hybrid buffer 6 in the Summary of the Invention) was treated in a water bath at 85 ° C for 15 min in a water bath and then left to cool at room temperature.
  • the samples were taken out from the -20 ° C refrigerator and thawed in a 4 ° C refrigerator. After complete dissolution, the sample and the hybrid buffer are mixed at a volume ratio of 1:1.5, vortexed and centrifuged, and the sample can be tested.
  • a blank control buffer, a corresponding concentration of the negative control (WT) and a positive control (MT) were added to the corresponding wells, and the amount of the sample was 20 ⁇ l.
  • WT negative control
  • MT positive control
  • the tip of the gun is attached to the bottom of the hole, but the bottom electrode is not touched.
  • the tilting or tapping of the detecting plate allows the liquid to uniformly cover the surface of the electrode in the hole, and then immediately goes to the EFIMR for electric field operation.
  • the corresponding column for the experiment was selected on the EFIRM software.
  • the electric field parameters were set to: voltage A: 200 mV, 5 s; voltage B: 300 mV, 5 s; 3 cycles were performed. After the electric field is processed, remove it immediately and clean the detection orifice.
  • the detection solution was PBS as a solvent, wherein the weight percentage of casein was 0.1%, the concentration of the detection probe was 0.5 ⁇ mol/L, vortexed and mixed, centrifuged, and set aside.
  • the corresponding column for the experiment was selected on the EFIRM software.
  • the electric field parameters were set to: voltage A: 200 mV, 5 s; voltage B: 300 mV, 5 s; 3 cycles were performed. After the electric field is processed, remove it immediately and clean the detection orifice.
  • the electric field parameter is set to: voltage A: -100mV, 40s, and the current reading is obtained.
  • Example 2 the methods provided in Examples 2 and 3 of the present invention were tested in the same manner as in Example 1, and the results obtained were basically in agreement with those in Example 1.
  • the human EGFR gene mutation detection kit provided by the invention and the detection of the human EGFR gene mutation using the kit are simple and convenient, the sample is non-invasive, and the required sample is small, and the whole detection process can be completed in half an hour; the sensitivity is good. , can reach 0.1%, high accuracy, more than 95%; low cost, compared with NGS, cost savings of more than 90%; easy to operate, low requirements for operators.
  • the detection orifice plate used in the method of the invention has the common feature that the inner bottom of the reaction well is provided with an electrode for applying an electric field to the solution in the reaction well after the EFIRM detector is turned on.
  • Existing commercial products can be used.
  • a detecting orifice structure comprising: a reaction well bottom plate 101, the reaction well bottom plate 101 includes at least one detecting region 102; and the working electrode 103
  • the working electrode 103 is disposed on the reaction well substrate 101 and configured to apply a voltage to form an electric field; and the opposite electrode 104 is disposed on the reaction aperture substrate 101 and configured to acquire a detection signal and output the detection signal.
  • the working electrode 103 and the opposite electrode 104 are both disposed on the same surface of the reaction cell bottom plate, and therefore, the working electrode 103 and the opposite electrode 104 may be in the same plane. As shown in FIG.
  • the working electrode 103 includes at least one first linear portion 1031 having a uniform width; the opposite electrode 104 includes at least one second linear portion 1041 of uniform width; the first linear portion 1031 and the second linear portion 1041 They are disposed within the detection zone 102 and are alternately spaced apart from one another.
  • the electrode 104 located on the right side of FIG. 1 can be configured as a working electrode to apply a voltage to form an electric field; the electrode 103 located on the left side of FIG. 1 can be The counter electrode is configured to acquire a detection signal and output the detection signal, and the disclosure is not limited herein.
  • the working electrode 103 can apply a voltage to generate an electric field to move and concentrate the target substance.
  • the working electrode 103 can apply a square wave alternating voltage to first include the target substance in the liquid to be detected.
  • the charged substance moves to the working electrode 103 to be enriched, so that the target substance can be combined with the probe on the working electrode 103, and then the polarity of the voltage is changed, so that other substances in the charged substance that are not combined with the probe are away from the working electrode 103 (
  • the force of the electric field on the target substance is set to be smaller than the binding force of the target substance and the probe; then, the opposite electrode 104 can acquire a detection signal about the target substance and output the detection signal, for example, a target substance bound to the probe.
  • the current reacts with a specific reagent to generate a current, so the opposite electrode 104 can acquire a detection signal about the target substance by detecting the current and output the detection signal; and then, by analyzing the output detection signal, the target substance can be obtained.
  • Information (such as the concentration of the target substance) so that it can be detected quickly and accurately. Since the first linear portion 1031 and the second linear portion 1041 are linear structures having a uniform width, and within the detection region 102, the first linear portion 1031 and the second linear portion 1041 are alternately equidistantly spaced within the detection region 102.
  • the first linear portion 1031 of the working electrode 103 can generate a uniform electric field in the detection region 102, and the second linear portion 1041 of the opposite electrode 104 can detect a minute current in the detection region 102, thereby improving The accuracy of the detection.
  • the density and uniformity of the probe formed on the working electrode 103 can be controlled, and the probe is not excessively dense. Thereby providing space for the binding of the target substance and the probe, and improving the efficiency of binding of the target substance and the probe, thereby improving the reaction speed of the liquid biopsy and further improving the detection accuracy.
  • the detecting electrode structure in the detecting orifice plate has a circular shape
  • the working electrode 103 may include an arc-shaped first main body portion 1030 and a plurality of extending from the first main body portion 1030.
  • the first linear portion 1031 that is parallel to each other.
  • the counter electrode 104 includes an arc-shaped second body portion 1040 and a plurality of second linear portions 1041 that are parallel to each other and extend from the second body portion 1040.
  • the first body portion 1030 is disposed opposite to the second body portion 1040, and the plurality of first linear portions 1031 and the plurality of second linear portions 1041 are disposed in the detection region 102 and are alternately spaced and equidistantly disposed.
  • the working electrode 103 and the opposite electrode 104 have a comb-like structure, and the working electrode 103 and the opposite electrode 104 cross each other to form an interdigitated structure.
  • the range of the detection area may include a plurality of first linear portions and a plurality of second linear portions, and may further include a first main body portion and a second main body portion, which are not limited herein.
  • the working electrode may not be provided with a fixing portion that is in direct contact with the probe, so the first linear portion may be formed into a line having a uniform width, thereby providing a more uniform electric field, so that the arrangement of the probe is more regular, thereby improving the efficiency and accuracy of detection. .
  • the detecting area 102 has a circular shape
  • the working electrode 103 includes a first linear portion 1031 which is spirally arranged
  • the opposite electrode 104 includes a second line which is spirally arranged.
  • the portion 1041, the first linear portion 1031 and the second linear portion 1041 are disposed in the detection region 102 and are alternately spaced and equidistantly disposed.
  • the width of the first linear portion is the same as the width of the second linear portion, so that the accuracy of the detection can be improved; in addition, the width of the first linear portion and the second linear portion
  • the range can be 3-20 mils (thousandths of an inch).
  • the pitch of the first linear portion and the second linear portion may range from 3 to 20 mils (thousandths of an inch).
  • the width of the first linear portion and the width of the second linear portion are equal to the spacing between the first linear portion and the second linear portion.
  • FIG. 3 is a schematic plan view of another detecting electrode structure
  • FIG. 4 is a schematic plan view of another detecting electrode structure.
  • the detecting electrode structure provided in an example of the embodiment further includes setting.
  • the reference electrode at the edge of the detection zone since the reference electrode is disposed at the edge of the detection zone, the outer side of the first linear portion and the second linear portion, the reference electrode can provide a contrast in the process of acquiring the detection signal about the target substance. The polarity error of the working electrode is eliminated, thereby further improving the accuracy of the detection.
  • the material of the working electrode and the opposing electrode includes gold. Since the chemical nature of the gold element is stable and does not react with the liquid to be detected and has a lower impedance, the accuracy of the detection can be further improved.
  • other conductive materials such as platinum or indium tin oxide may also be used.
  • FIGS. 5a and 5b illustrate a detection orifice plate used in the method of the present invention, the detection orifice plate comprising: a cartridge body 200 and a detection electrode structure 100, the cartridge body 200 comprising a plurality of reaction wells 211, the size of the reaction wells Reference may be made to the design of a conventional 96-well plate. Of course, the present disclosure includes but is not limited thereto, and the size of the reaction well may be designed according to the concentration and kind of the liquid to be detected. As shown in FIGS.
  • the detecting electrode structure 100 is disposed at the bottom of the casing 200
  • the detecting electrode structure 100 may be the detecting electrode structure of any of the above-described first embodiment
  • the detecting region 102 is disposed at the bottom of the reaction hole 211.
  • the bottom of the reaction well 211 is sealed.
  • the reaction cell bottom plate 101 of the detecting electrode structure 100 and the casing 200 can be made of the same material. Thereby, the liquid to be detected can be contained in the accommodating space composed of the detection zone 102 and the reaction well 211, thereby detecting the liquid to be detected.
  • the working electrode 103 may apply a square wave alternating voltage to form a vertical electric field perpendicular to the bottom surface of the through hole 211, first causing the charged substance including the target substance in the liquid to be detected from the respective positions of the reaction hole 211 to the reaction hole 211.
  • the bottom moves and moves to the working electrode 103 to enrich, so that the target substance can be combined with the probe on the working electrode 103 (a substance that can bind to the target substance, such as a DNA polymer molecule), and then the polarity of the voltage is converted to make it perpendicular to the pass.
  • the direction of the vertical electric field on the bottom surface of the hole 211 is reversed, so that other substances not charged with the probe in the charged substance in the liquid to be detected move from the bottom of the reaction hole 211 to the upper portion of the reaction hole 211, thereby causing other substances in the charged substance.
  • the substance not bound to the probe is away from the working electrode 103 (the force of the electric field on the target substance is set to be smaller than the binding force of the target substance and the probe); then, the opposite electrode 104 can acquire the detection signal about the target substance and detect
  • the signal output for example, the target substance bound to the probe reacts with a specific reagent to generate a current, so the opposite electrode 104 can pass the inspection.
  • the current is measured to obtain a detection signal about the target substance and the detection signal is output; then, the information about the target substance (for example, the concentration of the target substance) can be obtained by analyzing the output detection signal.
  • a plurality of reaction wells 211 are arranged in a matrix in the cartridge body 200.
  • the plurality of reaction holes 211 are cylindrical through holes.
  • the shape of the reaction well includes, but is not limited to, the shape of the plurality of reaction holes 211 may also be a square cylinder, a triangular cylinder or other cylinders.
  • the number of the plurality of reaction holes 211 is a multiple of four, as shown in FIG. 8, four adjacent reaction holes 211 correspond to the four working electrodes 103 in the detection electrode structure. Electrically connected.
  • the reaction hole bottom plate 101 is formed with a wire 111 and a wire 112.
  • the wire 111 electrically connects the four working electrodes 103.
  • the wires 112 are electrically connected to the four opposite electrodes 104 to extract the electrical signals of the opposite electrode 104.
  • the four adjacent through holes can be used as a detection group.
  • the voltages applied to the four working electrodes are uniform, and four adjacent through holes are The control experiment can be performed better, so the detection accuracy can be further improved.
  • any number of working electrodes in the detection electrode structure corresponding to any number of through holes may be electrically connected to provide a uniform voltage.
  • the detection aperture board used in the present invention further includes: a circuit board 110 electrically connected to the detection pole structure.
  • An amplification circuit may be disposed on the circuit board 110 to amplify the electrical signal outputted by the opposite electrode or the reference electrode to improve detection accuracy;
  • a voltage stabilization circuit may also be disposed on the circuit board 110 to provide a stable voltage to the working electrode to improve detection accuracy.
  • the present disclosure includes but is not limited thereto, and an overcurrent, overvoltage protection circuit, or the like may be disposed on the circuit board 110.
  • the circuit board 110 can be disposed under the reaction hole bottom plate 101, so that the space can be utilized more reasonably.
  • the circuit board 110 can also be disposed at other positions, and the disclosure is not limited herein.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une sonde pour la détection d'une mutation génétique de l'EGFR humain, un kit et un procédé de détection associés. La sonde comprend un ou plusieurs types de sondes dans 1 à 35 paires de sondes. Chaque paire de sondes comprend une sonde de capture et une sonde de détection, et les séquences nucléotidiques des paires de sondes 1 à 35 sont telles qu'indiquées dans SEQ ID NO : 1 à 70. L'invention concerne également un kit permettant la détection d'une mutation génétique de l'EGFR humain.
PCT/CN2017/104777 2016-09-30 2017-09-30 Sonde pour détection de mutation génétique de l'egfr humain, kit et procédé de détection associés WO2018059576A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610873223.8A CN106399518B (zh) 2016-09-30 2016-09-30 用于人egfr基因突变检测的探针、试剂盒及其检测方法
CN201610873223.8 2016-09-30

Publications (1)

Publication Number Publication Date
WO2018059576A1 true WO2018059576A1 (fr) 2018-04-05

Family

ID=59228765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/104777 WO2018059576A1 (fr) 2016-09-30 2017-09-30 Sonde pour détection de mutation génétique de l'egfr humain, kit et procédé de détection associés

Country Status (2)

Country Link
CN (1) CN106399518B (fr)
WO (1) WO2018059576A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111218520A (zh) * 2019-10-26 2020-06-02 大连海关技术中心 转基因大豆gts-40-3-2品系efirm检测探针及其应用
CN112986361A (zh) * 2021-04-27 2021-06-18 上海执诚生物科技有限公司 基于金-石墨烯量子点的电化学生物传感器在检测细胞中ctDNA中的应用
CN114088783A (zh) * 2021-11-25 2022-02-25 云南大学 一种生物传感器及其制备方法和应用、检测ctDNA的电化学系统
EP4146817A4 (fr) * 2020-05-07 2024-06-19 The Regents of The University of California Plate-forme de biopsie liquide dans le plasma et la salive
EP4153982A4 (fr) * 2020-05-21 2024-07-17 David Wong Test d'anticorps de sars-cov-2 ("covid-19") sur la salive et le sang à l'aide d'une technologie efirm

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014682A1 (fr) * 2016-07-20 2018-01-25 广州易活生物科技有限公司 Procédé de détection d'un gène cible au moyen d'une technique de pcr combinée à une technique efirm
CN106801099B (zh) * 2017-02-21 2020-08-14 北京易活生物科技有限公司 一种检测mthfr基因突变的核酸组合及其应用和试剂盒
CN106399518B (zh) * 2016-09-30 2019-11-22 广州易活生物科技有限公司 用于人egfr基因突变检测的探针、试剂盒及其检测方法
CN106755525B (zh) * 2017-02-21 2020-08-14 北京易活生物科技有限公司 一种检测mthfr基因突变的探针及其应用和试剂盒
CN109295055B (zh) * 2017-07-25 2024-02-06 广州普世利华科技有限公司 基于C2c2的肿瘤相关突变基因的gRNA、检测方法、检测试剂盒
CN108384852A (zh) * 2017-12-19 2018-08-10 上海百力格生物技术有限公司 一种用于肺癌egfr基因t790m位点检测的mgb引物和探针序列
CN109136369A (zh) * 2018-03-15 2019-01-04 江苏苏博生物医学股份有限公司 一种egfrt790m稀有突变高灵敏免提取检测试剂盒
CN110714056A (zh) * 2018-07-11 2020-01-21 大连易检科技有限公司 基于电化学与探针结合技术的转基因大豆快速检测方法和试剂盒
CN110714055A (zh) * 2018-07-11 2020-01-21 大连易检科技有限公司 基于电场诱导释放检测技术与探针结合技术的高通量转基因大豆检测方法和试剂盒
CN109411015B (zh) * 2018-09-28 2020-12-22 深圳裕策生物科技有限公司 基于循环肿瘤dna的肿瘤突变负荷检测装置及存储介质

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162613A2 (fr) * 2011-05-26 2012-11-29 Brandeis University Détection de variants de séquence dans le gène du récepteur du facteur de croissance épidermique humain (r-egf)
CN103517992A (zh) * 2011-01-06 2014-01-15 艾皮斯托姆有限公司 突变分析
CN104745679A (zh) * 2013-12-31 2015-07-01 北京贝瑞和康生物技术有限公司 一种无创检测egfr基因突变的方法及试剂盒
CN205844251U (zh) * 2016-07-20 2016-12-28 广州易活生物科技有限公司 检测电极结构以及检测孔板
CN106399518A (zh) * 2016-09-30 2017-02-15 广州易活生物科技有限公司 用于人egfr基因突变检测的探针、试剂盒及其检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103509858B (zh) * 2013-07-26 2015-01-21 北京普利耐特生物科技有限公司 一种人细胞色素酶p450基因多态性检测试剂盒
CN104789677A (zh) * 2015-04-20 2015-07-22 上海允英医疗科技有限公司 循环肿瘤dna egfr检测技术及其试剂盒

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103517992A (zh) * 2011-01-06 2014-01-15 艾皮斯托姆有限公司 突变分析
WO2012162613A2 (fr) * 2011-05-26 2012-11-29 Brandeis University Détection de variants de séquence dans le gène du récepteur du facteur de croissance épidermique humain (r-egf)
CN104745679A (zh) * 2013-12-31 2015-07-01 北京贝瑞和康生物技术有限公司 一种无创检测egfr基因突变的方法及试剂盒
CN205844251U (zh) * 2016-07-20 2016-12-28 广州易活生物科技有限公司 检测电极结构以及检测孔板
CN106399518A (zh) * 2016-09-30 2017-02-15 广州易活生物科技有限公司 用于人egfr基因突变检测的探针、试剂盒及其检测方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIN, C. C.: "Emerging platforms using liquid biopsy to detect EGFR muta- tions in lung cancer", EXPERT REVIEW OF MOLECULAR DIAGNOSTICS., vol. 15, no. 11, 30 September 2015 (2015-09-30), pages 1427 - 1440, XP055603167, ISSN: 1473-7159, DOI: 10.1586/14737159.2015.1094379 *
WEI, F. ET AL.: "Noninvasive Saliva-based EGFR Gene Mutation Detection in Pa- tients with Lung Cancer", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE., vol. 190, no. 10, 15 November 2014 (2014-11-15), pages 1117 - 1126, XP055429466, ISSN: 1073-449X, DOI: :10.1164/rccm.201406-1003OC *
WEI, F.ET AL.: "Electrochemical Sensor for Multiplex Biomarkers Detection", CLINICAL CANCER RESEARCH, vol. 15, no. 13, 1 July 2009 (2009-07-01), pages 4446 - 4452, XP055139487, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-0050 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111218520A (zh) * 2019-10-26 2020-06-02 大连海关技术中心 转基因大豆gts-40-3-2品系efirm检测探针及其应用
EP4146817A4 (fr) * 2020-05-07 2024-06-19 The Regents of The University of California Plate-forme de biopsie liquide dans le plasma et la salive
EP4153982A4 (fr) * 2020-05-21 2024-07-17 David Wong Test d'anticorps de sars-cov-2 ("covid-19") sur la salive et le sang à l'aide d'une technologie efirm
CN112986361A (zh) * 2021-04-27 2021-06-18 上海执诚生物科技有限公司 基于金-石墨烯量子点的电化学生物传感器在检测细胞中ctDNA中的应用
CN114088783A (zh) * 2021-11-25 2022-02-25 云南大学 一种生物传感器及其制备方法和应用、检测ctDNA的电化学系统

Also Published As

Publication number Publication date
CN106399518A (zh) 2017-02-15
CN106399518B (zh) 2019-11-22

Similar Documents

Publication Publication Date Title
WO2018059576A1 (fr) Sonde pour détection de mutation génétique de l'egfr humain, kit et procédé de détection associés
Mohan et al. Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC
CN103468813B (zh) Eml4-alk融合基因荧光定量pcr检测试剂盒
Miyake et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non‐muscle invasive bladder cancer
Liu et al. A dual-functional electrochemical biosensor for the detection of prostate specific antigen and telomerase activity
CN106755593B (zh) 一种hpv分型检测的核酸组合及其应用和试剂盒
Xu et al. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib
CN108486235A (zh) 一种高效经济检测融合基因的方法和体系
Guo et al. Detection of plasma EGFR mutations in NSCLC patients with a validated ddPCR lung cfDNA assay
Zhong et al. Discovery and validation of extracellular vesicle‐associated miRNAs as noninvasive detection biomarkers for early‐stage non‐small‐cell lung cancer
Concolino et al. Advanced tools for BRCA1/2 mutational screening: comparison between two methods for large genomic rearrangements (LGRs) detection
CN106636441B (zh) 一种检测aldh2基因突变的探针及其应用和试剂盒
CN103451268B (zh) 一种检测线粒体a3243g杂合突变率的标准品、试剂盒及其检测方法
CN106399589B (zh) 一种用于病毒基因分型检测的探针组合、试剂盒以及方法
EP3057985A1 (fr) Systèmes et procédés permettant de déterminer un plan thérapeutique d'action
CN108315432A (zh) ddPCR技术检测IDH1 R132C基因变异的引物、试剂盒及检测方法
Man et al. Simultaneous detection of VEGF and CEA by time-resolved chemiluminescence enzyme-linked aptamer assay
Zhu et al. Electrochemical determination of flap endonuclease 1 activity amplified by CRISPR/Cas12a trans‐cleavage
Wu et al. Biomolecules-mediated electrochemical signals of Cu2+: Y-DNA nanomachines enable homogeneous rapid one-step assay of lung cancer circulating tumor cells
CN106591485B (zh) 一种检测aldh2基因突变的核酸组合及其应用和试剂盒
CN107641649B (zh) 检测微卫星nr27位点稳定性的引物对、试剂盒及方法
Wang et al. Establishment and evaluation of digital PCR methods for HER2 copy number variation in breast cancer
WO2018014682A1 (fr) Procédé de détection d'un gène cible au moyen d'une technique de pcr combinée à une technique efirm
US20120252856A1 (en) Pi3k/akt pathway subgroups in cancer: methods of using biomarkers for diagnosis and therapy
CN110468182A (zh) 一种检测血小板衍生生长因子bb的均相生物分析方法及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17855026

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/05/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17855026

Country of ref document: EP

Kind code of ref document: A1